Correlates of protection against influenza

  • Emanuele Montomoli
Part of the Birkhäuser Advances in Infectious Diseases book series (BAID)


Correlates of protection for influenza virus has not been defined, but it is widely believed that protection against influenza can be conferred by serum hemagglutinin (HA) antibodies. The immune responses to injected influenza vaccines are routinely assessed using serological HA antibodies titration. It is generally accepted that neutralizing and HA antibodies, as well as antibodies to neuraminidase, can be detected in serum after 3–4 weeks post primary infection or vaccination.

Serological assays commonly used to quantify antibodies specific for influenza viruses include hemagglutination inhibition (HAI), single radial hemolysis (SRH), microneutralization (MN), ELISA and Western blot, the most widely used assays being HAI and SRH. Each method used for antibodies titration has different characteristics, and the validity index and specific use (seroepidemiology, serodiagnosis, response to vaccination, etc.) have to be considered to select the most suitable one. Recently ELISA and MN tests have been developed thanks to the discovery of the HA structure. While the number of data collected by conventional assays (HAI and SRH) has permitted a fairly good optimization, serological measures are used to characterize the number of antibodies before and after vaccination.

HAI is the assay used most frequently for influenza antibody titration; however, it has low sensitivity in detecting responses to avian viruses in mammalian sera and alternative serological tests are needed. SRH utilizes a complement-mediated hemolysis reaction to measure the amount of antibody. This test appears to be as sensitive as the MN assay. HAI and SRH assays are not functional tests for measuring immunity to influenza and suffers from several technical drawbacks.

Development of these assays will be a further step in preparation of new influenza vaccines, particularly for cell-derived products. Additional immunological assessments, such as cell-mediated immunity and the role of neuraminidase, need to be explored to give more insight into the overall effects of vaccination.


Influenza Virus Avian Influenza Influenza Vaccine Avian Influenza Virus Versus IRUS 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Treanor J (2004) Influenza vaccine-Outmaneuvering antigenic shift and drift. N Engl J Med 350: 218–220PubMedCrossRefGoogle Scholar
  2. 2.
    Webby RJ, Webster RG. (2003) Are we ready for pandemic influenza? Science 302: 1519–1522PubMedCrossRefGoogle Scholar
  3. 3.
    Barker WH, Mullooly JP (1980) Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol 112: 798–811PubMedGoogle Scholar
  4. 4.
    Barker WH (1986) Excess pneumonia and influenza-associated hospitalization during influenza epidemics in the United States, 1970-78. Am J Public Health 76: 761–765PubMedCrossRefGoogle Scholar
  5. 5.
    Dorrell L, Hassan I, Marshall S, Chakraverty P, Ong E (1997) Clinical and serological responses to an inactivated influenza vaccine in adults with HIV infection, diabetes, obstructive airways disease, elderly adults and healthy volunteers. Int J STD AIDS 8: 776–779PubMedCrossRefGoogle Scholar
  6. 6.
    Künzel W, Glathe H, Engelmann H, Van Hoecke C (1996) Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time. Vaccine 12: 1108–1110CrossRefGoogle Scholar
  7. 7.
    Stephenson I, Nicholson KG (2001) Influenza: Vaccination and treatment. Eur Respir J 17: 1282–1293PubMedCrossRefGoogle Scholar
  8. 8.
    Couch RB, Kasel JA, Glezen WP, Cate TR, Six HR, Taber LH, Frank AL, Greenberg SB, Zahradnik JM, Keitel WA (1986) Influenza: Its control in persons and populations. J Infect Dis 153: 431–440PubMedGoogle Scholar
  9. 9.
    Beyer WE, Palache AM, de Jong JC, Osterhaus AD (2002) Cold-adapted live influenza vaccine versus inactivated vaccine: Systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 20: 1340–1353PubMedCrossRefGoogle Scholar
  10. 10.
    Hoelscher MA, Garg S, Bangari DS, Belser JA, Lu X, Stephenson I, Bright RA, Katz JM, Mittal SK, Sambhara S (2006) Development of adenoviral-vectorbased pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367: 475–481PubMedCrossRefGoogle Scholar
  11. 11.
    Beyer WE, Palache AM, Lüchters G, Nauta J, Osterhaus AD (2004) Seroprotection rate, mean fold increase, seroconversion rate: Which parameter adequately expresses seroresponse to influenza vaccination? Virus Res 103: 125–132PubMedCrossRefGoogle Scholar
  12. 12.
    EMEA (1996) Note for Guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96)Google Scholar
  13. 13.
    EMEA (2003) Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application. (CPMP/VEG/4717/03)Google Scholar
  14. 14.
    Hirst GK (1941) The agglutination of red cells by allantoic fluid of chick embryos infected with influenza virus. Science 94: 22–23PubMedCrossRefGoogle Scholar
  15. 15.
    Wright PF, Bryant JD, Karzon DT (1980) Comparison of influenza B/Hong Kong virus infections among infants, children, and young adults. J Infect Dis 141: 430–435PubMedGoogle Scholar
  16. 16.
    Monto AS, Maassab HF (1981) Ether treatment of type B influenza virus antigen for the hemagglutination inhibition test. J Clin Microbiol 13: 54–57PubMedGoogle Scholar
  17. 17.
    Kendal AP, Cate TR (1983) Increased sensitivity and reduced specificity of hemagglutination inhibition tests with ether-treated influenza B/Singapore/222/79. J Clin Microbiol 18: 930–934PubMedGoogle Scholar
  18. 18.
    Palmer DF, Coleman MT, Dowdle WR, Schild GC (1975) Advanced laboratory techniques for influenza diagnosis. Immunology Series, Procedural Guide 6: U.S. Department of Health, Education, and Welfare; Public Health Service, Center for Disease Control, 34Google Scholar
  19. 19.
    Hinshaw VS, Webster RG, Easterday BC, Bean WJ Jr (1981) Replication of avian influenza A viruses in mammals. Infect Immun 34: 354–361PubMedGoogle Scholar
  20. 20.
    Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, Lim W, Fukuda K, Cox NJ, Katz JM (1999) Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 37: 937–943PubMedGoogle Scholar
  21. 21.
    Stephenson I, Wood JM, Nicholson KG, Zambon MC (2003) Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin. J Med Virol 70: 391–398PubMedCrossRefGoogle Scholar
  22. 22.
    Schild GC, Pereira MS, Chakraverty P (1975) Single-radial-hemolysis: A new method for the assay of antibody to influenza haemagglutinin. Applications for diagnosis and seroepidemiologic surveillance of influenza. Bull World Health Organ 52: 43–50PubMedGoogle Scholar
  23. 23.
    Mumford J, Wood J (1993) WHO/OIE meeting: Consultation on newly emerging strains of equine influenza. 18–19 May 1992, Animal Health Trust, Newmarket, Suffolk, UK. Vaccine 11: 1172–1175Google Scholar
  24. 24.
    Wood JM, Gaines-Das RE, Taylor J, Chakraverty P (1994) Comparison of influenza serological techniques by international collaborative study. Vaccine 12: 167–174PubMedCrossRefGoogle Scholar
  25. 25.
    Wood JM, Melzack D, Newman RW, Major DL, Zambon M, Nicholson KG, Podda A (2001) A single radial haemolysis assay for antibody to H5 haemagglutinin. International Congress Series 1219: 761–766CrossRefGoogle Scholar
  26. 26.
    Gross PA, Barry DW, D’Esopo N (1976) Influenza immunization in chronic bronchitis: Local and systemic immune response. Am Rev Respir Dis 114: 305–313PubMedGoogle Scholar
  27. 27.
    Benne CA, Harmsen M, de Jong JC, Kraaijeveld CA (1994). Neutralization enzyme immunoassay for influenza virus. J Clin Microbiol 32: 987–990PubMedGoogle Scholar
  28. 28.
    Harmon MW, Rota PA, Walls HH, Kendal AP (1988) Antibody response in humans to influenza virus type B host cell-derived variants after vaccination with standard (egg-derived) vaccine or natural infection. J Clin Microbiol 26: 333–337PubMedGoogle Scholar
  29. 29.
    Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M (2006) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354: 1343–1351PubMedCrossRefGoogle Scholar
  30. 30.
    Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, Hüschler K, Zambon MC (2006) Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: Phase I randomised trial. Lancet 367: 1657–1664PubMedCrossRefGoogle Scholar
  31. 31.
    Profeta ML, Palladino G (1986) Serological evidence of human infections with avian influenza viruses. Arch Virol 90: 355–360PubMedCrossRefGoogle Scholar
  32. 32.
    Frank AL, Puck J, Hughes BJ, Cate TR (1980) Microneutralization test for influenza A and B and parainfluenza 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement. J Clin Microbiol 12: 426–432PubMedGoogle Scholar
  33. 33.
    Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC (2004) Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 103: 91–95PubMedCrossRefGoogle Scholar
  34. 34.
    Doller G, Schuy W, Tjhen KY, Stekeler B, Gerth HJ (1992) Direct detection of influenza virus antigen in nasopharyngeal specimens by direct enzyme immunoassay in comparison with quantitating virus shedding. J Clin Microbiol 30: 866–869PubMedGoogle Scholar
  35. 35.
    Sakai RK, Gelfand DH, Stoffel S, Scharf FJ, Higuchi R, Horn GT, Mullis KB, Erlich HA (1988) Primer-directed enzymatic amplification of DNA with thermostable DNA polymerase. Science 239: 487–491CrossRefGoogle Scholar
  36. 36.
    Donofrio JC, Coonrod D., Davidson JN, Betts RF (1992) Detection of influenza A and B in respiratory secretions with the polymerase chain reaction. PCR Method Appl 1: 262–268Google Scholar
  37. 37.
    Wood JM, Robertson JS (2004) From lethal virus to life-saving vaccine: Developing inactivated vaccines for pandemic influenza. Nat Rev Microbiol 2: 842–847PubMedCrossRefGoogle Scholar
  38. 38.
    Hoffmann E, Krauss S, Perez D, Webby R, Webster RG (2002) Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine 20: 3165–3170PubMedCrossRefGoogle Scholar
  39. 39.
    Temperton NJ, Hoschler K, Major D, Nicolson C, Manvell R, Hien VM, Ha DQ, de Jong M, Zambon MC, Takeuchi Y, Weiss RA (2007) A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza 1: 105–112CrossRefGoogle Scholar
  40. 40.
    Sanders DA (2002) No false start for novel pseudotyped vectors. Curr Opin Biotechnol 13: 437–442PubMedCrossRefGoogle Scholar
  41. 41.
    Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, Zambon MC (2001) Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A randomised trial of two potential vaccines against H5N1 influenza. Lancet 357: 1937–1943PubMedCrossRefGoogle Scholar
  42. 42.
    Okuno Y, Tanaka K, Baba K, Maeda A, Kunita N, Ueda S (1990) Rapid focus reduction neutralization test of influenza A and B viruses in microtiter system. J Clin Microbiol 28: 1308–1313PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag Basel/Switzerland 2008

Authors and Affiliations

  • Emanuele Montomoli
    • 1
  1. 1.Department of Physiopathology, Experimental Medicine and Public Health, Laboratory of Molecular EpidemiologyUniversity of SienaSienaItaly

Personalised recommendations